Gilead Sciences, Inc. 13D and 13G filings for Kalaris Therapeutics Inc:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-03-20 4:32 pm Purchase | 2025-03-18 | 13G | Kalaris Therapeutics Inc KLRS | GILEAD SCIENCES INC. GILD | 723,273 3.900% | 723,273 (New Position) | Filing |